bexarotene


Also found in: Wikipedia.

bexarotene

 [bek-sar´ah-tēn]
a retinoid that modulates transcription and expression of genes involved in cellular differentiation and proliferation; used as an antineoplastic in the treatment of cutaneous T-cell lymphoma, administered orally. It is also used topically in the treatment of cutaneous lesions of T-cell lymphomas and Kaposi's sarcoma.

bexarotene

/bex·ar·o·tene/ (bek-sar´ah-tēn) a retinoid used as an antineoplastic in the treatment of cutaneous T-cell lymphoma and the cutaneous lesions of T-cell lymphomas and Kaposi's sarcoma.

bexarotene

a second-generation retinoid.
indications This drug is prescribed for cutaneous T cell lymphoma. Investigational uses include treatment of breast cancer.
contraindications Pregnancy and known hypersensitivity to retinoids prohibit bexarotene's use.
adverse effects Life-threatening adverse reactions include acute pancreatitis, leukopenia, and neutropenia. Other serious side effects include asthenia, infection, anemia, and hypothyroidism. Among the drug's common side effects are headache, nausea, abdominal pain, and diarrhea.

bexarotene

A retinoid that binds to retinoid X receptors, upregulating their activity by either removing negative transcription control or by facilitating transcription. It is FDA-approved for treating cutaneous T cell lymphoma, and has been used off label for lung and breast cancer, and Kaposi sarcoma.
Adverse effects Similar to hypervitaminosis A—headache, nausea, vomiting, lip inflammation, mucous-membrane dryness, joint pain, scaly skin, hyperlipidaemia
References in periodicals archive ?
Contract award notice: Pnsp 62/2017, Procurement of drugs: Bexarotene, Eribulin and lenvatinib
This approval is based on data from the randomized, open-label Phase 3 ALCANZA trial, which demonstrated that single agent Adcetris provided a highly statistically significant improvement in the overall response rate lasting at least four months versus the control arm of methotrexate or bexarotene as assessed by an independent review facility (p-value
5 months of follow-up, 56% of patients receiving brentuximab vedotin had an objective response lasting at least 4 months (the primary endpoint), versus 13% of patients treated with physician's choice of methotrexate or bexarotene (P less than .
Bexarotene, used to treat Cutaneous T-cell lymphoma causes central hypothyroidism.
In tests described February 4 in F1000Research, bexarotene, a lymphoma drug, didn't reduce levels of the Alzheimer's-related amyloid-beta protein.
Bexarotene, currently used to treat non-Hodgkin lymphoma has been investigated by researchers at the University of Cambridge and has been shown to interfere with the development of amyloid protein in worms, if given in the very early stages of the amyloid plaque formation.
A recent clinical trial of bexarotene in people with Alzheimer's was not successful, but this new work in worms suggests the drug may need to be given very early in the disease.
In lab tests, scientists found that bexarotene - used to treat lymphoma - stopped the build-up of these deadly deposits.
Bexarotene seems to help mice with Alzheimer's genes think better, but no one has known why.
launch of bexarotene 75 mg capsules, which are the generic version of Valeant's Targretin capsules.
Bexarotene therapy was started and good clinical and histological response was observed.
The high profile 2012 study in the US journal Science found that mice treated with bexarotene became rapidly smarter and the plaque in their brains that was causing Alzheimer's started to disappear within hours.